source
- FDA mandates label update for all GLP-1 drugs to warn of rare eye disease riskThe FDA issued a class‑wide labeling requirement for all approved GLP‑1 receptor agonists, adding a warning about non‑arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that…
- Delix Therapeutics secures $100 million Series C to advance psychedelic pipelineDelix Therapeutics announced it has closed a $100 million Series C financing round. The capital will be used to accelerate development of its pipeline of psychedelic and neuroplastogen candidates…